

DAFTAR PUSTAKA

- Achar S, Kundu S, Norcross W. (2005). *Diagnosis of acute coronary syndrome*. *Am Fam Physician* 72:119-26.
- Anker SD, Leyva F, Poole-Wilson PA, Kox WJ, Stevenson JC, Coats AJ. *Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure*. *Heart*.1997;78(1):39-43.
- Alwi, Idrus. (2009). *Infark Miokard Akut dengan Elevasi ST*. Jakarta Pusat: InternaPublishing.
- Anderson, Jeffrey L. ACC/AHA 2007 *Guidelines for The Management of Patients With Unstable Angina/Non-ST Elevation Myocardial Infarction*. A Report of The American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. In: *Circulation*. 2007.p.148-205
- Antman E, Anbe D, Armstrong P, et al. (2004). *ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction. A report of the American College of cardiology/ American Heart Assosiation task force inpractice guidelines*). *Am Coll Cardiol J* 44 (suppl I) :1-212
- Atman, E.M., Braunwald E. *ST-Segment Elevation Myocardial Infarction*. In: Kasper, Dennis L, eds. *Harrison's Principles of Internal Medicine*. 16th edition. USA: McGraw-Hill Companies. 2007. Hal. 1449-55
- Berne, M. (1980), “ *The role of adenosine in the regulation of coronary blood flow*”, *Circulation Research*, Vol.47,807-813.
- Berry CE and JM Hare. (2004). *Xanthine Oxidoreductase and Cardiovascular Disease: Molecular Mechanism and Pathophysiological Implications*. *Am JPhysiol*, pp: 589-606.
- Bertrand ME Simoons ML Fox KAA Wallentin LC et al. *Management Of Acute Coronary Syndrome In Patiens Presenting Without Persistent StSegmen Elevation*. *European Heart Journal* 2002; 23: 1406 – 1432, 1809-1840.
- Brown CT. *Penyakit aterosklerotik koroner*. In: *Patofisiologi: Konsep Klinis proses-proses Penyakit Volume 1* (6th ed). Jakarta: EGC. 2005;576-87.
- C Chrysohoou , DB Panagiotakos , C Pitsavos , et al. (2003) *Gender differences on the risk evaluation of acute coronary syndromes: the CARDIO2000 study*. *Prev Cardiol* 6, 71–77.

- Cantu-Medellin N, Kelley EE. *Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation*. Redox biology. 2013;1(1):353-8.
- Castelli, P; Condemi, AM; Brambillasca, C; Fundaro,P; Botta, M; Lemma, M; Vanelli, P; Santoli,C; Gatti, S and Riva, E (1995), “ *Improvement of cardiac function by allupurinol in patients undergoing cardiac surgery*”, Journal of Cardiovascular Pharmacology, Vol. 25, 119-125.
- Costa, F; Sulur, P; Angel, M; Cavalcate, J; Haile, V; Christman, B and Biaggioni, I (1999), “ *Intravascular source of adenosine during forearm ischemia in humans implications for reactive hyperemia*”, Hypertension, Vol. 33, 1453-1457.
- Departmen Kesehatan. *Pharmaceutical Care untuk Pasien Penyakit Jantung Koroner : Fokus Acute coronary sindrom*. Jakarta: Direktorat Bina Farmasi Komunitas dan Klinik Ditjen Bina Kefarmasian dan Alat Kesehatan Departemen Kesehatan RI. (2006). Hal 1-101
- Departemen Kesehatan RI. (2008). Riset Kesehatan Dasar 2007.
- Diaz MN, Frei B, Vita JA, Keaney JF. (1997). *Antioxidants and atherosclerosis heart disease*. N Engl J Med ;337(6):408-416.
- Emmerson, BT (1996), “ *The management of Gout*”, New England Journal of Medicine, Vol. 334,445-451.
- Feig DI, Duk HK, JohnsonRJ. (2008). *Uric Acid and Cardiovascular Risk*. NEJM;359:1811-21.
- Francis H. McCrudden, (2000). *Uric Acid*. Penerjemah Suseno Akbar, Salemba Medika: Yogyakarta
- Fredholm,BB and Sollevi, A (1986), “ *Cardiovascular effects of adenosine* “, Metabolism, Vol. 30,616-634.
- Gertler MM, Garn SM, Levine SA. (1951). *Serum uric acid in relation to age and physique in health and in coronary heart disease*. Ann Intern Med.;34:1421-1431.
- Gur M, Yilmaz R, Demirbag R, Aksoy N. *Relation of serum uric acid levels with the presence and severity of angiographic coronary artery disease*. Angiology 2008; 59(Suppl 2):166-71.

- Hamm W, Heeschen C, Falk E, Fox K. (2004). *Acute coronary syndrome : Pathophysiology, Diagnosis and risk stratification*. Elsevier, p.333-367.
- Hansson GK. (2005). *Inflammation, Atherosclerosis, and Coronary Artery Disease*. *N Engl J Med*; 352 (16): 1685-95.
- Hidayat, A., Aziz, A. (2007). *Metode Penelitian Keperawatan dan teknik Analisa Data*. Penerbit: Salemba Medika.
- Hooper DC, Scott GS, Zborek A, Mkhieva T, Kean RB, Koprowski H, et al. *Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis*. *FASEB J*. 2000;14:691– 698.
- Ismail D. (2001). Patofisiologi Sindroma Koroner Akut. Dalam : Bawazier LA, Alwi I, Syam AF dkk. Editors. *Prosiding Simposium Pendekatan Holistik Penyakit Kardiovaskuler*. Jakarta : Pusat Informasi dan Penerbitan Bagian Ilmu Penyakit Dalam FK UI ; 2001.hal.22
- Ishizaka N, Ishizaka Y, Toda EI, Nagai R, Yamakado M. *Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals*. *Arteriosclerosis, thrombosis, and vascular biology*. 2005;25(5):1038-44.
- Kang DH, Ha SK. *Uric Acid Puzzle: Dual Role as Anti-oxidant and Pro-oxidant*. *Electrolytes & Blood Pressure*. 2014;12(1):1- 6.
- Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. (2010). *Hyperuricemia and coronary heart disease: a systematic review and meta-analysis*. *Arthritis Care Res.*;62(2):170-180. doi:10.1002/acr.20065.
- Kojima S, Sakamoto T, Ishihara M, et al. (2005). *Prognostic usefulness of serum uric acid after acute myocardial infarction (Japanese Acute coronary Syndrome Study)*. *Am J Cardiol*;96:489-95.
- Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. (2008). *Long-term Cardiovascular Mortality Among Middle-aged Men with Gout*. *Arch Intern Med.*;168(10):1104-10.
- Levine G, Eric R, James C et al. (2011). *ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions*. *Circulation*.124:1-82.

- Li Chen, Xian-lin Li, Qiao W, Ying Z, Qin Y-L, Wang Y, Zeng Y-J, Ke Y-n. (2012). *Serum uric acid in patients with acute ST-elevation myocardial infarction*. *Word J Emerg Med*, Vol 3, No 1.
- Madjid, Abdul. *Penyakit Jantung Koroner: Patofisiologi, Pencegahan, dan Pengobatan Terkini*. Medan:Universitas Sumatra Utara. 2007.Hal 1-10.
- Mandell, Brian F. (2008). *Cleveland Clinic Journal of Medicine: Clinical manifestations of hyperuricemia and gout. Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, Cleveland Clinic: Cleveland, OH*
- McCaig LF, Burt CW. (2001). *National Hospital Ambulatory Medical Care Survey: 1999 emergency department summary*. *Adv.Data* 320, 1–34.
- Messner B, Bernhard D. *Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis*. *ATVB AHA Journal*. 2014;34;509-15
- Murray Robert K, Granner Daryl K, Rodwell Victor W. (2006). *Harper's: Illustrated Biochemistry*. 27 Edition. McGraw Hill, Lange : Boston, Burr ridge, Il dubuque, La madison, WL, New York, San Francisco, St. Louis, Bangkok, Bogota, Caracas, Kuala Lumpur, Lisbon, London, Madrid, Mexico City, Milan, Montreal, New Delhi, Santiago, Seoul, Singapore, Sydney, Taipei, Toronto.
- Nawawi RA., Fitriani, dkk. *Nilai Troponin T (cTnT) Penderita Acute coronary sindrom (ACS)*. 2005. Hal 123-4.
- Notoatmodjo. (2005). *Metodologi Penelitian Kesehatan*. Jakarta: Rineka Cipta.
- Nursalam. (2013). *Konsep & Penerapan Metodologi Penelitian Ilmu Keperawatan: Pedoman Skripsi, Tesis, dan Instrumen Penelitian Keperawatan*. Jakarta: Salemba Medika
- Packard R.R.S, Libby P. (2008). *Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction*. *Clinical Chemistry* 54: 24-38.
- Ramadhani BYS, Rotty LWA, Wantania F. (2010) *Gambaran hematologi pada paisein sindrom koroner akut yang dirawat di BLU RSUP Prof. Dr. R. D. Kandou Manado*. *Journal e-Biomedik*. 2013;1:12-6

- Rauch U, Osende JI, Fuster V, et al. (2001). *Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences*. *Ann Intern Med* 134 : 224-38.
- Sastroasmoro, S., (2014). *Dasar-Dasar Metodologi Penelitian Klinis*. Jakarta: Sagung Seto, pp.99-100.
- Spahic, E., Hasic, S., Kiseljakovic, E., Resic, H., Kulic, M., “Positive correlation between uric acid and C-reactive protein serum level in healthy individuals and patients with acute coronary syndrome”.
- Steele, TH (1999), “Hyperuricemic nephropathies”, *Nephrology*, Vol.81,45-49.
- Stefanus, E.I, *Arthritiss Gout*, In *Buku Ajar Ilmu Penyakit Dalam, Pusat Penerbitan Ilmu Penyakit Dalam FK UI*, Jakarta, 2006: 1218 – 20.
- Ter Arkh .(2011). *Clinical implication of endothelial dysfunction in patients with essential arterial Hypertension and urate dysbolism with renal damage*. :83(10):36-40. [Article in Russian]
- Therax P, Foster V. (1998). *Acute Coronary Syndrome: Unstable Angina and non QWave Myocard Infarction*. *Circulation* 97: 1195-1206.
- Thygesen K., Alpert JS., White HD. *Universal Definition of Myocardial Infarction on Behalf of The Joint ESC/ACCF/AHA/WHF Task Force for The Redefinition of Myocardial Infarction*. In *Circulation*. 2007;116. P.2634-44.
- Waring, WS; Webb, DJ and Maxwell, SRJ (2000), “ Uric acid as a risk factor for cardiovascular disease”, *Qatar Journal of Medicine*, Vol. 93, 707-713.
- Weir CJ, Muir SW, Walters MR, Lees KR. *Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke*. 2003;34(8):1951-6.
- World Health Organization. *Deaths from Coronary Heart Disease*. (2013). Available from <http://www.who.int/mediacentre/factsheets/fs310/en/index.html>.
- Wright RS, Cynthia DA, Jeffrey LA et al. (2011). *ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline)*. *J. Am. Coll. Cardiol.* 57;1920-1959.

Zafar, M., *et al.* (2014). "*Association of hyperuricemia with acute coronary syndrome*".